Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients.

Sánchez-Céspedes J, Marrugal-Lorenzo JA, Martín-Gandul C, Rodríguez-Torres N, Montero-Mateos E, Serna-Gallego A, Escamilla-Gómez V, Merino L, Espigado I, Pachón J, Pérez-Simón JA, Aguilar-Guisado M.

Haematologica. 2020 Jan 23. pii: haematol.2019.240101. doi: 10.3324/haematol.2019.240101. [Epub ahead of print] No abstract available.

2.

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.

Bento L, Bastida JM, García-Cadenas I, García-Torres E, Rivera D, Bosch-Vilaseca A, De Miguel C, Martínez-Muñoz ME, Fernández-Avilés F, Roldán E, Chinea A, Yáñez L, Zudaire T, Vaz CP, Espigado I, López J, Valcárcel D, Duarte R, Cabrera R, Herrera C, González-Porras JR, Gutiérrez A, Solano C, Sampol A; Grupo Español de Trasplante Hematopoyético (GETH).

Biol Blood Marrow Transplant. 2019 Sep;25(9):1825-1831. doi: 10.1016/j.bbmt.2019.05.023. Epub 2019 May 29.

PMID:
31152794
3.

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Martínez-Laperche C, Buces E, Aguilera-Morillo MC, Picornell A, González-Rivera M, Lillo R, Santos N, Martín-Antonio B, Guillem V, Nieto JB, González M, de la Cámara R, Brunet S, Jiménez-Velasco A, Espigado I, Vallejo C, Sampol A, Bellón JM, Serrano D, Kwon M, Gayoso J, Balsalobre P, Urbano-Izpizua Á, Solano C, Gallardo D, Díez-Martín JL, Romo J, Buño I; GVHD/Immunotherapy Committee of the Spanish Group for Hematopoietic Transplantation.

Blood Adv. 2018 Jul 24;2(14):1719-1737. doi: 10.1182/bloodadvances.2017011502.

4.

Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome.

Falantes JF, Márquez-Malaver FJ, Calderón-Cabrera C, Pedrote B, Martino ML, González J, Espigado I, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):469-474.e1. doi: 10.1016/j.clml.2018.05.004. Epub 2018 May 10.

PMID:
29807802
5.

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.

Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, Vázquez-López L, Montero MI, Rosso-Fernández C, de la Luz Martino M, Parody R, González-Campos J, Garzón-López S, Calderón-Cabrera C, Barba P, Rodríguez N, Rovira M, Montero-Mateos E, Carratalá J, Pérez-Simón JA, Cisneros JM.

Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: 10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15.

PMID:
29153975
6.

Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study.

Jurado M, De La Mata C, Ruiz-García A, López-Fernández E, Espinosa O, Remigia MJ, Moratalla L, Goterris R, García-Martín P, Ruiz-Cabello F, Garzón S, Pascual MJ, Espigado I, Solano C.

Cytotherapy. 2017 Aug;19(8):927-936. doi: 10.1016/j.jcyt.2017.05.002. Epub 2017 Jun 26.

PMID:
28662983
7.

[Consensus opinion on antifungal prophylaxis in haematologic patients: Results of the PROMIC project].

Vázquez López L, Villaescusa de la Rosa T, de la Cámara R, Espigado I, Grau Cerrato S, Jurado M, Rovira M, Salavert M, Serrano Simonneau D, Solano Vercet C, Ruiz Camps I.

Rev Esp Quimioter. 2017 Jun;30(3):213-223. Epub 2017 May 23. Spanish.

8.

The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.

Falantes JF, Márquez-Malaver FJ, Knight T, Calderón-Cabrera C, Martino ML, González J, Montero I, Espigado I, Pérez-Simón JA.

Leuk Lymphoma. 2017 Aug;58(8):1893-1902. doi: 10.1080/10428194.2016.1267350. Epub 2016 Dec 12.

PMID:
27951729
9.

Differences in stem cell transplantation activity among regions in Spain: an economic explanation.

Espigado I, Ortega-Ortega M, Montero-Granados R, Rodriguez-Torres N, Márquez-Malaver FJ.

Bone Marrow Transplant. 2016 Nov;51(11):1537-1539. doi: 10.1038/bmt.2016.177. Epub 2016 Jul 4. No abstract available.

PMID:
27376450
10.

Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation.

Sarmiento M, Parody R, Márquez-Malaver F, Espigado I, Falantes J, Caballero T, Calderón C, Carmona M, López Haldon J, Pérez-Simón JA.

Bone Marrow Transplant. 2016 Jun;51(6):863-5. doi: 10.1038/bmt.2016.8. Epub 2016 Feb 8. No abstract available.

PMID:
26855153
11.

Mortality of Oncohematological Patients Undergoing Hematopoietic Stem Cell Transplantation Admitted to the Intensive Care Unit.

Corcía Palomo Y, Knight Asorey T, Espigado I, Martín Villén L, Garnacho Montero J.

Transplant Proc. 2015 Nov;47(9):2665-6. doi: 10.1016/j.transproceed.2015.09.033.

PMID:
26680067
12.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.

Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferrà C, García-Noblejas A, Jimenez S, Sampol A, Yañez L, García-Gutiérrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF.

Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8. doi: 10.1016/j.bbmt.2015.11.012. Epub 2015 Nov 26.

13.

The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.

Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín-Antonio B, Guillem V, Bosch-Vizcaya A, Bento L, González-Rivera M, Balsalobre P, Kwon M, Serrano D, Gayoso J, de la Cámara R, Brunet S, Rojas-Contreras R, Nieto JB, Martínez C, Gónzalez M, Espigado I, Vallejo JC, Sampol A, Jiménez-Velasco A, Urbano-Ispizua A, Solano C, Gallardo D, Díez-Martín JL, Buño I; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH).

PLoS One. 2015 Oct 16;10(10):e0140454. doi: 10.1371/journal.pone.0140454. eCollection 2015.

14.

Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.

Falantes JF, Trujillo P, Piruat JI, Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez M, González J, Martino ML, Montero I, Parody R, Espigado I, Urbano-Ispizua A, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.

PMID:
25487600
15.

Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure.

Calderón-Cabrera C, Carmona González M, Martín J, Ríos Herranz E, Noguerol P, De la Cruz F, Carrillo E, Falantes JF, Parody R, Espigado I, Pérez-Simón JA.

Transfusion. 2015 Apr;55(4):875-9. doi: 10.1111/trf.12906. Epub 2014 Oct 29.

PMID:
25354577
16.

Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.

Parody R, Martino R, de la Cámara R, García-Noblejas A, Esquirol A, Garcia-Cadenas I, Villaescusa T, Caballero D, Rovira M, Fernandez-Avilés F, Marquez-Malaver FJ, Espigado I, Castilla-Llorente C, Heras I, Cabero MA, Cabrera JR, Barba P, Valcarcel D, Sánchez-Ortega I, Duarte RF, Serrano D, Carretero F, Vazquez L.

Bone Marrow Transplant. 2015 Feb;50(2):274-81. doi: 10.1038/bmt.2014.229. Epub 2014 Oct 27.

PMID:
25347007
17.

Intra-arterial bone marrow mononuclear cell transplantation correlates with GM-CSF, PDGF-BB, and MMP-2 serum levels in stroke patients: results from a clinical trial.

Moniche F, Montaner J, Gonzalez-Marcos JR, Carmona M, Piñero P, Espigado I, Cayuela A, Escudero I, de la Torre-Laviana FJ, Boada C, Rosell A, Mayol A, Jimenez MD, Gil-Peralta A, Gonzalez A.

Cell Transplant. 2014;23 Suppl 1:S57-64. doi: 10.3727/096368914X684934. Epub 2014 Oct 20.

PMID:
25335778
18.

Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.

Espigado I, de la Cruz-Vicente F, BenMarzouk-Hidalgo OJ, Gracia-Ahufinger I, Garcia-Lozano JR, Aguilar-Guisado M, Cisneros JM, Urbano-Ispizua A, Perez-Romero P.

Transpl Int. 2014 Dec;27(12):1253-62. doi: 10.1111/tri.12406. Epub 2014 Oct 21.

19.

Antifungal combination therapy for invasive aspergillosis.

Martín-Peña A, Aguilar-Guisado M, Espigado I, Cisneros JM.

Clin Infect Dis. 2014 Nov 15;59(10):1437-45. doi: 10.1093/cid/ciu581. Epub 2014 Jul 21. Review.

PMID:
25048847
20.

Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.

Martínez-Bravo MJ, Calderón-Cabrera C, Márquez-Malaver FJ, Rodríguez N, Guijarro M, Espigado I, Núñez-Roldán A, Pérez-Simón JA, Aguilera I.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1356-62. doi: 10.1016/j.bbmt.2014.05.008. Epub 2014 May 17.

21.

Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.

Calderón-Cabrera C, Márquez-Malaver FJ, de la Cruz-Vicente F, Falantes F, Carrillo E, Parody R, Montero I, González Campos J, Martino ML, Carmona M, Pérez-Simón JA, Espigado I.

Transplant Proc. 2013;45(10):3665-7. doi: 10.1016/j.transproceed.2013.11.007.

PMID:
24314990
22.

Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.

Falantes JF, Calderón C, Márquez-Malaver FJ, Aguilar-Guisado M, Martín-Peña A, Martino ML, Montero I, González J, Parody R, Pérez-Simón JA, Espigado I.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1.

PMID:
24220615
23.

Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia.

Martín-Peña A, Gil-Navarro MV, Aguilar-Guisado M, Espigado I, de Pipaón MR, Falantes J, Pachón J, Cisneros JM.

Antimicrob Agents Chemother. 2013 Oct;57(10):4664-72. doi: 10.1128/AAC.00723-13. Epub 2013 Jul 15.

24.

To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors.

Parody R, Caballero D, Márquez-Malaver FJ, Vázquez L, Saldaña R, Madrigal MD, Calderón C, Carrillo E, Lopez-Corral L, Espigado I, Carmona M, López-Villar O, Pérez-Simón JA.

Eur J Haematol. 2013 Nov;91(5):448-55. doi: 10.1111/ejh.12140. Epub 2013 Oct 1.

PMID:
23710624
25.

A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT.

Martín-Antonio B, Suarez-Lledo M, Arroyes M, Fernández-Avilés F, Martínez C, Rovira M, Espigado I, Gallardo D, Bosch A, Buño I, Martínez-Laperche C, Jiménez-Velasco A, de la Cámara R, Brunet S, Nieto JB, Urbano-Ispizua A.

Bone Marrow Transplant. 2013 Sep;48(9):1205-11. doi: 10.1038/bmt.2013.43. Epub 2013 Apr 1.

PMID:
23542224
26.

Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.

Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, Carrillo E, Martino ML, Montero I, González J, Parody R, Espigado I, Pérez-Simón JA.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):144-52. doi: 10.1016/j.clml.2012.09.013. Epub 2012 Nov 6.

PMID:
23137720
27.

Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial.

Moniche F, Gonzalez A, Gonzalez-Marcos JR, Carmona M, Piñero P, Espigado I, Garcia-Solis D, Cayuela A, Montaner J, Boada C, Rosell A, Jimenez MD, Mayol A, Gil-Peralta A.

Stroke. 2012 Aug;43(8):2242-4. doi: 10.1161/STROKEAHA.112.659409. Epub 2012 Jul 3.

PMID:
22764211
28.

A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.

Martín-Antonio B, Álvarez-Laderas I, Cardesa R, Márquez-Malaver F, Baez A, Carmona M, Falantes J, Suarez-Lledo M, Fernández-Avilés F, Martínez C, Rovira M, Espigado I, Urbano-Ispizua Á.

Bone Marrow Transplant. 2012 Sep;47(9):1206-11. doi: 10.1038/bmt.2011.253. Epub 2012 Jan 9.

PMID:
22231458
29.

Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy.

Ljungman P, Locasciulli A, de Soria VG, Békássy AN, Brinch L, Espigado I, Ferrant A, Franklin IM, O'Riordan J, Rovira M, Shaw P, Einsele H; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2012 Sep;47(9):1217-21. doi: 10.1038/bmt.2011.238. Epub 2011 Dec 12.

PMID:
22158388
30.

Pneumonia in allogeneic stem cell transplantation recipients: a multicenter prospective study.

Aguilar-Guisado M, Jiménez-Jambrina M, Espigado I, Rovira M, Martino R, Oriol A, Borrell N, Ruiz I, Martín-Dávila P, de la Cámara R, Salavert M, de la Torre J, Cisneros JM; Spanish Network for Research in Infectious Diseases.

Clin Transplant. 2011 Nov-Dec;25(6):E629-38. doi: 10.1111/j.1399-0012.2011.01495.x. Epub 2011 Aug 21.

PMID:
22150886
31.

Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach.

Aguilar-Guisado M, Martín-Peña A, Espigado I, Ruiz Pérez de Pipaon M, Falantes J, de la Cruz F, Cisneros JM.

Haematologica. 2012 Mar;97(3):464-71. doi: 10.3324/haematol.2011.049999. Epub 2011 Nov 4.

32.

Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.

Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A; Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.

Antivir Ther. 2011;16(7):951-7. doi: 10.3851/IMP1858.

PMID:
22024510
33.

Influence of glutathione S-transferase T1 donor/recipient mismatch and anti-GSTT1 antibodies in hepatic graft-versus-host-disease.

Martínez-Bravo MJ, Tallón I, Espigado I, Perez-Simón JA, Pérez-Romero P, Gracia-Ahufinger I, Aguilera I, Núñez-Roldán A.

Immunol Lett. 2011 Dec 30;141(1):140-4. doi: 10.1016/j.imlet.2011.09.005. Epub 2011 Sep 24.

PMID:
21968078
34.

[Comparison of two initial mobilizing strategies of peripheral blood stem cells for autologous transplantation in patients with lymphoma and human immunodeficiency virus infection].

Sagüés M, Sancho JM, Serrano D, Balsalobre P, Gayoso J, Morgades M, Conde E, Iriondo A, Varela R, Escoda L, Xicoy B, Espigado I, Fernández-Abellán P, Díez JL, Ribera JM.

Med Clin (Barc). 2012 Jul 21;139(5):192-6. doi: 10.1016/j.medcli.2011.05.013. Epub 2011 Jul 31. Spanish.

PMID:
21807388
35.

Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients.

Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation.

Haematologica. 2011 Aug;96(8):1231-5. doi: 10.3324/haematol.2011.041913. Epub 2011 May 5.

36.

Differences in cytomegalovirus replication quantified using quantitative polymerase chain reaction and antigenemia after allogeneic stem cell transplantation.

de la Cruz-Vicente F, Perez-Romero P, Aguilar-Guisado M, Cisneros-Herreros JM, Urbano-Ispizua A, Espigado I.

Transplant Proc. 2010 Oct;42(8):3230-1. doi: 10.1016/j.transproceed.2010.05.140.

PMID:
20970661
37.

Clinical utility of real-time polymerase chain reaction to quantify cytomegalovirus replication in allogeneic stem cell transplant recipients with different prevention strategies.

De la Cruz-Vicente F, Perez-Romero P, Aguilar-Guisado M, Cisneros-Herreros JM, Urbano-Ispizua A, Espigado I.

Transplant Proc. 2010 Oct;42(8):3228-9. doi: 10.1016/j.transproceed.2010.05.050.

PMID:
20970660
38.

Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies.

Falantes JF, Carrillo E, Márquez F, Carmona M, Espigado I.

Transplant Proc. 2010 Oct;42(8):3225-7. doi: 10.1016/j.transproceed.2010.05.045.

PMID:
20970659
39.

Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors.

Martín-Antonio B, Carmona M, Falantes J, Gil E, Baez A, Suarez M, Marín P, Espigado I, Urbano-Ispizua A.

Haematologica. 2011 Jan;96(1):102-9. doi: 10.3324/haematol.2010.026401. Epub 2010 Sep 17.

40.

Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients.

Martín-Peña A, Aguilar-Guisado M, Espigado I, Parody R, Miguel Cisneros J.

Clin Transplant. 2011 May-Jun;25(3):468-74. doi: 10.1111/j.1399-0012.2010.01286.x. Epub 2010 May 10.

PMID:
20482561
41.

Differences in cytomegalovirus plasma viral loads measured in allogeneic hematopoietic stem cell transplant recipients using two commercial real-time PCR assays.

Gracia-Ahufinger I, Tormo N, Espigado I, Solano C, Urbano-Ispizua A, Clari MA, de la Cruz-Vicente F, Navarro D, Pérez-Romero P.

J Clin Virol. 2010 Jun;48(2):142-6. doi: 10.1016/j.jcv.2010.03.015. Epub 2010 Apr 14.

PMID:
20395168
42.

Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.

Ferrá C, Sanz J, de la Cámara R, Sanz G, Bermúdez A, Valcárcel D, Rovira M, Serrano D, Caballero D, Espigado I, Morgades M, Heras I, Solano C, Duarte R, Barrenetxea C, García-Noblejas A, Díez-Martin JL, Iriondo A, Carreras E, Sierra J, Sanz MA, Ribera JM; GETH (Grupo Español de Trasplante Hematopoyético) and PETHEMA (Programa Español de Tratamiento en Hematología), Spanish Society of Hematology.

Biol Blood Marrow Transplant. 2010 Jul;16(7):957-66. doi: 10.1016/j.bbmt.2010.02.003. Epub 2010 Feb 7.

43.

Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.

Gallardo D, de la Cámara R, Nieto JB, Espigado I, Iriondo A, Jiménez-Velasco A, Vallejo C, Martín C, Caballero D, Brunet S, Serrano D, Solano C, Ribera JM, de la Rubia J, Carreras E.

Haematologica. 2009 Sep;94(9):1282-8. doi: 10.3324/haematol.2009.006924.

44.

Glutathione S-transferase T1 is a potential new target for the hepatic component of graft vs host disease after HSCT.

Aguilera I, Espigado I, Martinez-Bravo MJ, Tallon I, Urbano-Ispizua A, Nuñez-Roldan A.

Bone Marrow Transplant. 2010 Apr;45(4):774-5. doi: 10.1038/bmt.2009.206. Epub 2009 Aug 17. No abstract available.

PMID:
19684638
45.

Empirical antifungal therapy in selected patients with persistent febrile neutropenia.

Aguilar-Guisado M, Espigado I, Cordero E, Noguer M, Parody R, Pachón J, Cisneros JM.

Bone Marrow Transplant. 2010 Jan;45(1):159-64. doi: 10.1038/bmt.2009.125. Epub 2009 Jun 15.

PMID:
19525983
46.

Autologous stem-cell transplantation in patients with HIV-related lymphoma.

Balsalobre P, Díez-Martín JL, Re A, Michieli M, Ribera JM, Canals C, Rosselet A, Conde E, Varela R, Cwynarski K, Gabriel I, Genet P, Guillerm G, Allione B, Ferrant A, Biron P, Espigado I, Serrano D, Sureda A.

J Clin Oncol. 2009 May 1;27(13):2192-8. doi: 10.1200/JCO.2008.18.2683. Epub 2009 Mar 30. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3263.

PMID:
19332732
47.

Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation.

Díez-Martín JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sureda A; European Group for Blood and Marrow Transplantation Lymphoma Working Party.

Blood. 2009 Jun 4;113(23):6011-4. doi: 10.1182/blood-2008-12-195388. Epub 2009 Mar 23.

PMID:
19307667
48.

High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.

Espigado I, Ríos E, Marín-Niebla A, Carmona M, Parody R, Pérez-Hurtado JM, Márquez FJ, Urbano-Ispizua A.

Transplant Proc. 2008 Nov;40(9):3104-5. doi: 10.1016/j.transproceed.2008.08.092.

PMID:
19010208
49.

[Cost-effectiveness of empirical antifungal treatment of haematology patients with a high risk of invasive fungal infection].

Espigado I.

Farm Hosp. 2008 Jan-Feb;32(1):4-6. Spanish. No abstract available.

PMID:
18426696
50.

Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.

Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, Pérez-Oteyza J, Espigado I, Romero A, Caballero D, Sierra J, Ribera JM, Díez JL.

Biol Blood Marrow Transplant. 2007 Jun;13(6):701-6.

Supplemental Content

Loading ...
Support Center